PPMD For You:
Schedule a one-to-one meeting
for personalized support.powered by Calendly

April 8, 2025 /

Webinar: Wave Life Sciences – Update on FORWARD-53 Study of WVE-N531

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

Wave Life Sciences recently joined PPMD for a community webinar to provide an update on the company’s Phase 2 FORWARD-53 trial of WVE-N531, Wave’s exon skipping oligonucleotide being investigated for the treatment of individuals with Duchenne who are amenable to exon 53 skipping. Wave discussed the recently released FORWARD-53 data and answered questions from the community.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List